A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors

NCT ID: NCT07014878

Last Updated: 2025-06-11

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-30
• Study Completion Date: 2028-05-31

Brief Summary

This study is an open-label, single-arm, multicenter Phase I clinical trial consisting of a dose-escalation phase (Phase Ia) and a cohort-expansion phase (Phase Ib).

Phase Ia (Dose Escalation) aims to evaluate the safety and tolerability of DCTY1102 Injection in patients with advanced solid tumors positive for KRAS G12D mutation and HLA-A*11:01 genotype, observe potential dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), characterize the pharmacokinetic (PK) profile of DCTY1102 following infusion, assess its in vivo proliferation and persistence, preliminarily evaluate therapeutic efficacy, and investigate immunogenicity.

Phase Ib (Cohort Expansion) will be conducted after establishing MTD and/or RP2D in Phase Ia. This phase further evaluates the preliminary efficacy, safety, PK profile, and immunogenicity of DCTY1102 Injection in patients with KRAS G12D mutation-positive, HLA-A*11:01 genotype tumors, including colorectal cancer, pancreatic cancer, or other malignancies. The study plans to establish 2-3 cohorts:

Cohort 1: Colorectal cancer

Cohort 2: Pancreatic cancer

Cohort 3: Other tumor types

Each cohort will enroll approximately 15-31 patients who will receive DCTY1102 infusion at the MTD and/or RP2D dose levels identified in Phase Ia.

Conditions

PDAC; CRC (Colorectal Cancer); NSCLC; Solid Tumor Malignancies

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TCR-T treatment group

To evaluate the safety and tolerability of DCTY1102 injection in patients with advanced solid tumors positive for KRAS G12D mutation and genotype HLA-A\*11:01, observe potential dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), characterize the pharmacokinetic (PK) profile of DCTY1102 injection following infusion, assess its proliferation and persistence in vivo, preliminarily evaluate therapeutic efficacy, and investigate immunogenicity.

Group Type: EXPERIMENTAL

TCR-T cells

Intervention Type: BIOLOGICAL

Dose escalation will follow the standard "3+3" design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially.

Interventions

TCR-T cells

Dose escalation will follow the standard "3+3" design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Informed consent:Written informed consent form (ICF) must be signed prior to any study-related procedures (including pre-screening and main screening).
• Age:18 ≤ Age ≤ 75 years
• Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have experienced failure of standard treatment (disease progression after treatment or intolerable toxic side effects), have no standard treatment available, for whom standard treatment is not applicable at present, or who refuse standard treatment.
• Have at least one measurable lesion (according to RECIST v1.1).
• The prescreening must meet the following two criteria simultaneously: HLA-A 11:01 genotype, and not carrying the HLA-A 68:01 subtype; Positive for the tumor KRAS G12D mutation.
• ECOG 0-2 with life expectancy ≥3 months.
• LVEF ≥50% by echocardiography
• SpO₂ ≥92% on room air
• Laboratory Parameters: ANC ≥1.5×10⁹/L, ALC ≥0.7×10⁹/L, Platelets ≥75×10⁹/L, Hemoglobin ≥85 g/L, TBIL ≤1.5×ULN, ALT/AST ≤2.5×ULN, Cr ≤1.5×ULN, Ccr ≥50 mL/min, APTT ≤1.5×ULN, INR ≤1.5×ULN
• Child-Pugh Class A or favorable B (score ≤7)
• For patients with advanced primary hepatocellular carcinoma, Child-Pugh liver function classification must be Class A or relatively well-preserved Class B (score ≤7).
• Pre-menopausal fertile women who have not undergone sterilization surgery must agree to use effective contraception from the start of lymphodepleting chemotherapy until one year after cell infusion, and have a negative serum pregnancy test within 14 days before cell infusion
• Men who have not undergone sterilization surgery must agree to use effective contraception from the start of lymphodepleting chemotherapy until one year after cell infusion.

Exclusion Criteria

• Received last dose of anti - tumor therapy (chemotherapy, endocrine therapy, targeted therapy, immunotherapy, tumor embolization, or traditional Chinese medicine with anti - tumor indications, etc.) within 4 weeks before lymphodepleting chemotherapy.
• Received live - attenuated vaccine within 4 weeks before apheresis.
• Previously received any genetically engineered T - cell therapy or therapy targeting KRAS G12D mutation.
• Known allergy to any component of the study treatment.
• Not recovered from adverse events of previous surgery or therapy to ≤Grade 1 CTCAE v5.0 (excluding any - grade alopecia, ≤Grade 2 peripheral sensory neuropathy, and toxicities deemed safe by the investigator).
• History of leptomeningeal or central nervous system (CNS) metastases, or definite CNS disease within 6 months before cell infusion with residual symptoms. Asymptomatic brain metastases or stable symptoms after treatment (surgery/radiation) without steroid use are allowed.
• Poorly controlled hypertension (systolic BP>160 mmHg and/or diastolic BP>100 mmHg) or clinically significant cardiovascular disease (e.g., stroke, myocardial infarction within 6 months before signing the consent form, unstable angina, NYHA Class Ⅱ or higher heart failure, or severe arrhythmia not controlled by medication or potentially impacting study treatment). ECG shows clinically significant abnormalities in 3 consecutive readings (at least 5 - min intervals) or average QTcF≥450ms.
• Have other severe organic or psychiatric diseases.
• Have systemic active infection requiring IV antibiotics.
• Known HIV infection (anti - HIV antibody - positive), active hepatitis B (HBsAg - positive or HBcAb - positive with HBV - DNA - positive), active hepatitis C (anti - HCV antibody - positive with HCV - RNA - positive), or syphilis infection (anti - TP - positive).
• Diagnosed with severe autoimmune disease requiring long - term (over 2 months) systemic immunosuppressants (steroids) or immune - mediated symptomatic disease (e.g., ulcerative colitis, Crohn's disease, rheumatoid arthritis, SLE, autoimmune vasculitis like Wegener's granulomatosis).
• Used systemic steroids (inhaled or topical use excluded), hydroxyurea, immunomodulators (e.g., α/γ - interferons, GM - CSF, mTOR inhibitors, cyclosporine, thymopeptide, etc.) within 2 weeks before apheresis or plan to use during the study.
• History of allogeneic organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.
• Uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or hepatic failure
• Known alcohol and/or drug abuse.
• Pregnant or breastfeeding women.
• Have any concurrent medical condition or disease that the investigator considers may affect the trial.
• Patients without legal capacity or with limited legal capacity.
• Investigator deems the patient unable to complete all study visits/procedures (including follow - up) or has insufficient adherence, or considers the patient unsuitable for inclusion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing DCTY Biotech Co.,Ltd.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

First Medical Center of Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Shengjie Sun MD, PhD

Role: CONTACT

ssjdoctor@163.com

0086-010-66939409

Facility Contacts

Shengjie Sun MD, PhD

Role: primary

ssjdoctor@163.com

+86 01066939409

Other Identifiers

C2025-009-01

Identifier Type: -

Identifier Source: org_study_id